Immunocore Holdings Ltd Total Liabilities
Immunocore Holdings Ltd total liabilities. Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has total liabilities worth $699.62 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Immunocore Holdings Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Immunocore Holdings Ltd (2013–2025)
Total liabilities of Immunocore Holdings Ltd from 2013 to 2025. This chart illustrates how Immunocore Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Check IMCR financial resilience to evaluate the company's liquid asset resilience ratio.
Immunocore Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Immunocore Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ennostar Inc
TW:3714
|
Taiwan | NT$9.23 Billion |
|
Globant SA
F:2G2
|
Germany | €1.16 Billion |
|
Deterra Royalties Ltd
AU:DRR
|
Australia | AU$236.22 Million |
|
Triumph Financial, Inc.
NYSE:TFIN
|
USA | $5.93 Billion |
|
Opera Ltd
NASDAQ:OPRA
|
USA | $148.76 Million |
|
PT Bank SMBC Indonesia Tbk
JK:BTPN
|
Indonesia | Rp178.97 Trillion |
|
GKG Precision Machine Co. Ltd. A
SHE:301338
|
China | CN¥1.14 Billion |
|
Jungfraubahn Holding AG
SW:JFN
|
Switzerland | CHF204.17 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Immunocore Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Immunocore Holdings Ltd assets under control.
Liquidity & Leverage Metrics
Immunocore Holdings Ltd Total Liabilities Ratios Explained
Immunocore Holdings Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunocore Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunocore Holdings Ltd (2013–2025)
The table below shows the annual total liabilities of Immunocore Holdings Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $686.24 Million | +5.77% |
| 2024-12-31 | $648.79 Million | +184.36% |
| 2023-12-31 | $228.16 Million | +21.45% |
| 2022-12-31 | $187.86 Million | +6.89% |
| 2021-12-31 | $175.76 Million | +23.91% |
| 2020-12-31 | $141.85 Million | -37.34% |
| 2019-12-31 | $226.37 Million | +62.63% |
| 2018-12-31 | $139.19 Million | +130.11% |
| 2017-12-31 | $60.49 Million | +37.18% |
| 2016-12-31 | $44.10 Million | -25.30% |
| 2015-12-31 | $59.04 Million | -6.26% |
| 2014-12-31 | $62.98 Million | +646.24% |
| 2013-12-31 | $8.44 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more